KR20120078691A - Compositions supportive for anticancers containing decursin and/or decursinol angelate, or angelica extract containing decursin and/or decursinol angelate - Google Patents

Abstract

PURPOSE: An anticancer therapeutic adjuvant composition containing decursin and/or decursinol angelate or Angelica gigas nakai extract containing decursin and/or decursinol angelate is provided to relieve side effect. CONSTITUTION: An anticancer therapeutic adjuvant composition for treating bladder cancer or prostate cancer contains a mixture of decursin of chemical formula 1 and decursinol angelate of chemical formula 2, or Angelica gigas Nakai extract containing the compounds. The composition is administered before or after administering an anticancer therapeutic agent.

Description

An anticancer adjuvant composition comprising a decancin and / or decosinol angelate, or a Angelica extract comprising the decansin and / or decosinol angelate as an active ingredient. ANGELICA EXTRACT CONTAINING DECURSIN AND / OR DECURSINOL ANGELATE}

The present invention relates to an anticancer therapeutic adjuvant composition comprising a decoxin and / or a decosinol angelate, or a Angelica extract comprising the decansin and / or decosinol angelate as an active ingredient.

The side effects of chemotherapy and radiation therapy in chemotherapy, whether successful chemotherapy or not, can greatly deteriorate the quality of life of the patient and, in turn, serve as another fatal etiology.

One of the fatal side effects is the suppression of bone marrow. Because bone marrow is an organ that is actively producing cells, it is particularly sensitive to anticancer drugs, and thus cancer patients are suffering from symptoms and diseases caused by insufficient production of red blood cells, white blood cells, and platelets. Exposed. As is generally known, there are anemia caused by red blood cell reduction, immunological weakness by leukocyte reduction, and bleeding risk due to platelet reduction.

In addition to the suppression of bone marrow as a life-threatening chemotherapy patients, side effects on the liver and kidney are typical. If the liver is directly toxic by detoxifying anticancer drugs, and liver function is reduced by liver invasion, viral hepatitis, cirrhosis, etc. of the cancer, and thus the degradation of anticancer drugs in the liver is inhibited, and other side effects of the anticancer drugs are severely shown. There are many. When kidney function, which is an organ that excretes waste products of the body, is dropped by anticancer drugs, cancer or other factors, the excretion of anticancer drugs may be delayed, causing a vicious cycle in which side effects of anticancer drugs are maximized, and symptoms of uremia due to delayed excretion of waste products May appear. There are also a number of known side effects that affect the heart, reproductive organs, and nervous system, depending on the individual characteristics of the chemotherapy or radiation therapy.

Therefore, in patients requiring chemotherapy, the management of the side effects is as important as chemotherapy itself, unlike other diseases, except for adjuvant therapy for general mild nausea, vomiting, bone marrow, liver, kidney Materials that can be widely used as anticancer adjuvants having prophylactic and therapeutic protection against the back have not been generally put to practical use.

In the pharmacological action of decursin, decursinol angelate, decurcinol, and / or two or more of the Angelica gigas extracts, which are the main components of Angelica gigas Nakai There have been many studies on the disease, which is effective for leukemia cancer cells (Patent Publication No. 2001-0080265), for analgesic activity (Patent No. 10-0397950), and even for lung cancer and liver cancer (patent registration notice). 10-0187881) and neuroprotective action (Patent Publication 2002-0078850) and the like.

However, it is a composition using decancin and / or decosinol angelate, or Angelica extract, which is a decosin and / or decosinol angelate as an active ingredient, especially for hematopoietic function, liver and kidney which are greatly affected by anticancer treatment. No pharmacological or clinical findings have been found for use as an anticancer adjuvant that provides a beneficial effect.

Therefore, the inventors of the present invention can reduce side effects of anti-cancer treatment in decancin and / or decusinol angelate, which is a medicinal herb that has been widely used safely for a long time, as an herbal medicine, or as an active ingredient, a bengal extract. If the effect can be confirmed, it was determined that it would be possible to provide a safer and more widely available adjuvant and led to the present invention.

In accordance with the above object, the present invention provides an anticancer therapeutic adjuvant composition comprising a Angelica extract containing Decasin represented by the following Chemical Formula 1 or Decasin represented by the following Chemical Formula 1 as an active ingredient.

(1)

(One)

The present invention also provides an anticancer therapeutic adjuvant composition comprising a Angelica extract, which contains Decusinol Angelate or Decusinol Angelate represented by Formula 2 as an active ingredient.

(2)

(2)

In addition, the present invention provides an anticancer therapeutic adjuvant composition comprising a Angelica extract comprising the above-mentioned decusin and / or decusinol angelate, or as the active ingredient of decusin and / or decusinol angelate.

In addition, the composition of the present invention, the decusinol or decosinol represented by the formula (3) to the above-mentioned decusin and / or decusinol angelate, or a sugar extract extract containing decosin and / or decosinol angelate It may further include a Angelica extract containing the glow.

(3)

(3)

The above-mentioned decusin, decosinol angelate or decosinol can be obtained by extracting, separating and purifying from Angelica gigas. (1970); and Korean J. Pharmacogn ., 21, 64-68 (1990)) and Patent Registration No. 10-2385092, but is not limited thereto, even if the solvent, extraction conditions and the like, the decker Any extraction method can be used to obtain cine, decosinol angelate or decosinol.

The Angelica extract may further include all salts, organic salts, complexes, and the like, which are known to be incidental in the extraction process, in addition to the above-mentioned decusin, decosinol angelate or decosinol.

The above decosin, decosinol angelate or decosinol can be synthesized and used as a specific method (Tetsuhiro Nemoto et al., Tetrahedron ). Letters , 41, 9569-9574 (2000); Lan Xie et al . J. Med . Chem ., 42, 2662-2672 (1999); Patent application No. 2000-25749; And Patent Registration No. 10-0417624), but the present invention is not limited thereto, and any method may be used as long as the above-described method can be used to obtain the above-described decusin, decosinol angelate or decosinol. Do.

The decancin and / or decusinol angelate, or the decancin extract containing decusin and / or decusinol angelate, have particularly desirable effects on renal failure, hepatic insufficiency, or hematopoietic insufficiency of cancer patients. Indicates.

It is preferable to administer the above-mentioned decusin and / or decusinol angelate, or the Angelica extract containing decusin and / or decusinol angelate, before or after administration of the anticancer agent.

In the case of using the synthesized decansin, decosinol angelate or decosinol as the anticancer therapeutic adjuvant composition, all inorganic salts, organic salts, complexes, and the like, which are known to be involved in the synthesis of the raw materials, may be further included. Can be.

The above compounds are inorganic salts selected from the group consisting of sodium salts, potassium salts, magnesium salts, calcium salts or organic salts selected from the group containing lysine, ethanolamine, N, N'-dibenzylethylenediamine, It may be in the form of a pharmaceutically acceptable salt.

In addition, the present invention comprises a decancin and / or Decusinol Angelate, or a Angelica extract as the active ingredient of Decusin and / or Decusinol Angelate, and further comprises a pharmaceutically acceptable carrier or pharmaceutical additive An anticancer adjuvant is provided.

In the present invention, the anticancer adjuvant further comprises a decancin and / or decosinol angelate, or a Angelica extract comprising the decansin and / or decosinol angelate as an active ingredient, and a pharmaceutically acceptable food additive. Food is provided.

The composition comprising the decancin and / or decusinol angelate used in the present invention, or the Angelica extract, which is used as an active ingredient of the decusin and / or decusinol angelate, according to the target disease, the purpose and the condition of the patient. The dosage can be changed and used, and it is preferable to administer 1 to 100 mg, more preferably 3 to 30 mg once per day, usually 1 deg. In addition, the above dosage may be administered orally or parenterally formulated.

In addition, the composition comprising the decancin and / or decusinol angelate, or the Angelica extract as the active ingredient decosin and / or decosinol angelate used in the present invention, reduced uric acid during the clinical trial process of the present inventors Positive effects were observed for the clinical trials of the patient. Further investigation of the present inventors is further underway.

The composition of the present invention protects the liver function, renal function, hematopoietic function during chemotherapy, and can significantly reduce side effects of chemotherapy.

In addition, four out of 33 patients who received the composition of the present invention reported a total of four (12.1%) side effects, including one gastrointestinal side effect, one sleep disorder, and one urinary system side effect. One other case was reported, but since it was targeted to patients undergoing chemotherapy, no direct association with the composition of the present invention was confirmed. It was confirmed that no.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples do not limit the scope of the present invention.

Dosing method

A foam comprising 300 mg of a mixture of Decasin and Decusinol Angelate obtained by culturing and extracting a Korean Angelica extract as described in Patent Registration No. 10-0385092 was prepared. About 50ml of drinking water around 9 am and / or 8 pm daily was administered to the following subjects once or twice a day and once or three times per day for 8 weeks.

Example  One

As shown in Table 1 below, 10 cancer patients undergoing chemotherapy and / or radiation therapy were checked for changes in SGOT / SGPT before and after administration of the composition of the present invention, and the results are shown in Table 1.

Patient ID Disease name gender SGOT change
SGPT change
result Before administration After administration Before administration After administration One Bladder cancer south 17 5 21 15 decrease 2 Lymphoma south 26 18 50 32 decrease 3 Rectal cancer female 33 29 51 37 decrease 4 Rectal cancer female 30 19 47 28 decrease 5 Breast cancer female 25 14 46 14 decrease 6 Rectal cancer south 35 28 70 58 decrease 7 Breast cancer female 38 33 72 64 decrease 8 Chronic liver abscess south 45 31 52 41 decrease 9 Prostate cancer south 34 25 66 28 decrease 10 Prostate cancer south 31 24 49 25 decrease

Example  2

As shown in Table 2 below, for various types of cancer patients, changes in hemoglobin levels in blood before and after administration of the composition of the present invention were confirmed, and the results are shown in Table 2.

Patient ID Morning star Disease name Hb value in blood judgment Before administration After administration One south Bladder cancer 8.8 10.3 increase 2 south Bladder cancer 6.8 7.8 increase 3 south Rectal cancer 9.8 10.9 increase 4 south Prostate cancer 8.6 11.6 increase 5 south Prostate cancer 8.9 10.8 increase 7 south Urethral cancer 10.6 12.3 increase 8 south Lung cancer 8.6 10.8 increase 9 female Breast cancer 10.3 10.9 increase 10 female Breast cancer 13 13.3 increase 11 female Breast cancer 12.1 12.6 increase 12 female Breast cancer 12.0 13.0 increase

Example  3

Nine cancer patients were given the composition of the present invention for two weeks in advance, followed by administration of one or two anti-cancer drugs (16 times in total), and the average of the results obtained after confirming the change of SGOT before and after each anticancer drug administration. Table 3 shows.

Number of doses SGOT Decrease Count SGOT ascents result 1 to 2 times for a total of 9 people
(16 times in total) 13 (81.3%) 3 (18.7%) Good

(%)

Example  4

Nine cancer patients were given the composition of the present invention for two weeks in advance, followed by administration of one or two (16 total) anticancer drugs, and the change in serum creatinine clearance before and after each anticancer agent was confirmed and averaged. One result is shown in Table 4.

Number of doses CrC Reduction Frequency (%) % Of CrC increase result 1 to 2 times for a total of 9 people
(16 times in total) 13 (81.3%) 3 (18.7%) Good

(%)

Example  5

Nine cancer patients were given a composition of the present invention for two weeks in advance, followed by administration of one or two anti-cancer drugs (16 times in total), and the average change in the hemoglobin concentration before and after each anticancer drug was confirmed and averaged. Is shown in Table 5.

Number of doses Hb increase (%) Hb Reduction Frequency (%) result 1 to 2 times for a total of 9 people
(16 times in total) 13 (81.3%) 3 (18.7%) Good

(%)

According to Example 1 (Table 1), a decrease in overall SGOT / SGPT was confirmed in cancer patients to whom the composition of the present invention was administered. It can be seen that the protective effect was shown. More interestingly, liver composition of cancer patients was shown by presenting the composition of the present invention for cancer patients for 2 weeks in this Example 3-4 (Tables 3-4), showing 81.3% SGOT reduction and creatinine clearance. In addition to restoring renal function impairment, it has been shown to have a prophylactic effect, and as an adjuvant therapy before and after chemotherapy, the prophylactic and therapeutic effect is found in Examples 2 and 5 (Tables 2 and 5). It was also confirmed from the side. In particular, among 16 anticancer administrations, 13 cases showed anti-anemia effect, and the recovery of hemoglobin and hemoglobin level was remarkably quicker than that of the patient group not administered the composition of the present invention.

Therefore, the composition of the present invention, protects liver function, renal function, hematopoietic function during anti-cancer treatment, can significantly reduce the side effects of anti-cancer treatment.

In addition, four out of 33 patients who received the composition of the present invention reported a total of four (12.1%) side effects, including one gastrointestinal side effect, one sleep disorder, and one urinary system side effect. One other case was reported, but since it was targeted to patients undergoing chemotherapy, no direct association with the composition of the present invention was confirmed. It was confirmed that no.

Claims (3)

As an active ingredient, a mixture of decusin represented by the following general formula (1) and decosinol angelate represented by the following general formula (2), or decosin represented by the following general formula (1) and decosinol angelate represented by the following general formula (2) An anticancer therapeutic adjuvant composition comprising a Angelica extract, comprising kidney cancer or prostate cancer as a target disease.

(One)

(2) The anticancer adjuvant composition according to claim 1, wherein the anticancer adjuvant composition is administered before or after the administration of the anticancer agent. Deucin and decosinol angelate, or decansin and decosinol angelate containing the extract as an active ingredient, characterized in that it further comprises a pharmaceutically acceptable carrier or medicament, kidney cancer or An anticancer adjuvant composition for treating prostate cancer.